Dyslipidemia

By addressing insulin resistance, researchers believe they can reduce the comorbidities associated with type 2 diabetes.

Dr. Giorgino discusses how combining SGLT2 Inhibitors and GLP-1RA could be combined for treating type 2 diabetes.

Diabetic patients are more susceptible to severe COVID-19 outcomes.

Dr. Kausik Ray presents new data on inclisiran and bempedoic acid as cholesterol lowering medications.

New research from the Mayo Clinic is outlining the successes and pitfalls of efforts to improve statin adherence in a comparison of data from the OptumLab Data Warehouse from 2007-2016.

2020 was the year when regulators, clinicians, and patients had no choice but to embrace the concept of wearable monitoring devices. But it’s been a long time coming for the technology class.

Dr. Paul D. Thompson tackles the topic of whether use of fenofibrate helps or harms kidney function.

More studies are planned testing the impact of finerenone.

Finerenone could be another option to SGLT2 inhibitors for this patient population.

Researchers present new data from the SUSTAIN 6 and PIONEER 6 trials during the virtual AHA 2020 conference.

The rates of ALT normalization maintained in both arms of the 96 week study.

The lipid profile changes were not significant after 6 months, while the changes in the lipid profile are due to other factors and not the drugs.

Ongoing debates question whether or not lipid lowering in elderly patients offers similar clinical benefit as in younger patients.

In data from several studies presented at AHA 2020, investigators tout bempedoic acid in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia.

Data from a phase 2 trial suggests evinacumab, in both subcutaneous and intravenous doses, were effective at lowering LDL-C in patients with refractory hypercholesterolemia.

Results of the RIVER trial suggest rivaroxaban was noninferior to warfarin for the study's composite endpoint of all-cause mortality, major cardiovascular events, and major bleeding.

In data presented at AAO 2020, researchers discover new methods for detecting different underlying conditions.

SimpleSENSE is a first-of-its-kind cloth-based diagnostic platform that can capture more than 100 million data points per patient per day across cardiac, pulmonary, and circulatory biomarkers.

Older patients benefit greater from LDL-cholesterol lowering medications.

Practical Cardiology's Chief Advisory Board member Dr. Guy Mintz and a principal investigator from the CLEAR program discuss bempedoic acid and how they envision it fitting into treatment algorithms going forward.